Nxera Pharma Co., Ltd. (4565.T)
JPY 1056.0
(1.15%)
JPY 1056.0
(1.15%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 90.38 Billion JPY | 117.9% |
| 2022 | 41.48 Billion JPY | 4.97% |
| 2021 | 39.51 Billion JPY | 64.08% |
| 2020 | 24.08 Billion JPY | 107.58% |
| 2019 | 11.6 Billion JPY | -33.35% |
| 2018 | 17.4 Billion JPY | -15.5% |
| 2017 | 20.6 Billion JPY | 7.06% |
| 2016 | 19.24 Billion JPY | -20.11% |
| 2015 | 24.08 Billion JPY | -16.68% |
| 2014 | 28.9 Billion JPY | 12618.2% |
| 2013 | 227.28 Million JPY | -19.68% |
| 2012 | 282.95 Million JPY | -1.79% |
| 2011 | 288.11 Million JPY | -14.08% |
| 2010 | 335.33 Million JPY | 13.18% |
| 2009 | 296.27 Million JPY | 29.54% |
| 2008 | 228.72 Million JPY | -85.89% |
| 2007 | 1.62 Billion JPY | -15.17% |
| 2006 | 1.91 Billion JPY | 129.93% |
| 2005 | 831.24 Million JPY | 442.14% |
| 2004 | 153.32 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 84.57 Billion JPY | -3.34% |
| 2024 Q2 | 87.5 Billion JPY | 1.27% |
| 2024 Q1 | 86.4 Billion JPY | -4.41% |
| 2023 Q3 | 91.48 Billion JPY | 120.97% |
| 2023 Q4 | 90.38 Billion JPY | -1.2% |
| 2023 FY | 90.38 Billion JPY | 117.9% |
| 2023 Q2 | 41.4 Billion JPY | 2.21% |
| 2023 Q1 | 40.5 Billion JPY | -2.35% |
| 2022 FY | 41.48 Billion JPY | 4.97% |
| 2022 Q4 | 41.48 Billion JPY | 5.1% |
| 2022 Q1 | 39.29 Billion JPY | -0.56% |
| 2022 Q2 | 34.86 Billion JPY | -11.27% |
| 2022 Q3 | 39.46 Billion JPY | 13.2% |
| 2021 FY | 39.51 Billion JPY | 64.08% |
| 2021 Q1 | 24.35 Billion JPY | 1.13% |
| 2021 Q2 | 25.59 Billion JPY | 5.07% |
| 2021 Q3 | 35.18 Billion JPY | 37.48% |
| 2021 Q4 | 39.51 Billion JPY | 12.32% |
| 2020 Q2 | 10.13 Billion JPY | -4.7% |
| 2020 Q1 | 10.63 Billion JPY | -8.3% |
| 2020 Q4 | 24.08 Billion JPY | -4.02% |
| 2020 FY | 24.08 Billion JPY | 107.58% |
| 2020 Q3 | 25.09 Billion JPY | 147.48% |
| 2019 Q3 | 16.89 Billion JPY | -0.31% |
| 2019 FY | 11.6 Billion JPY | -33.35% |
| 2019 Q2 | 16.95 Billion JPY | -6.93% |
| 2019 Q1 | 18.21 Billion JPY | 0.0% |
| 2019 Q4 | 11.6 Billion JPY | -31.34% |
| 2018 Q1 | 20.6 Billion JPY | -11.57% |
| 2018 Q3 | 17.78 Billion JPY | -6.61% |
| 2018 Q2 | 19.04 Billion JPY | -7.55% |
| 2018 FY | 17.4 Billion JPY | -15.5% |
| 2017 Q1 | 19.24 Billion JPY | -12.81% |
| 2017 FY | 20.6 Billion JPY | 7.06% |
| 2017 Q4 | 23.29 Billion JPY | -2.11% |
| 2017 Q3 | 23.79 Billion JPY | 1.56% |
| 2017 Q2 | 23.43 Billion JPY | 21.78% |
| 2016 FY | 19.24 Billion JPY | -20.11% |
| 2016 Q4 | 22.06 Billion JPY | 6.73% |
| 2016 Q1 | 24.08 Billion JPY | 30.24% |
| 2016 Q3 | 20.67 Billion JPY | -19.24% |
| 2016 Q2 | 25.6 Billion JPY | 6.3% |
| 2015 Q2 | 28.83 Billion JPY | -0.26% |
| 2015 FY | 24.08 Billion JPY | -16.68% |
| 2015 Q3 | 19.12 Billion JPY | -33.67% |
| 2015 Q4 | 18.49 Billion JPY | -3.29% |
| 2015 Q1 | 28.9 Billion JPY | 4226.72% |
| 2014 Q4 | 668.08 Million JPY | 33.11% |
| 2014 Q3 | 501.91 Million JPY | -2.01% |
| 2014 Q2 | 512.2 Million JPY | 125.36% |
| 2014 Q1 | 227.28 Million JPY | 24.56% |
| 2014 FY | 28.9 Billion JPY | 12618.2% |
| 2013 FY | 227.28 Million JPY | -19.68% |
| 2013 Q1 | 282.95 Million JPY | 2.57% |
| 2013 Q2 | 347.37 Million JPY | 22.76% |
| 2013 Q4 | 182.46 Million JPY | -46.04% |
| 2013 Q3 | 338.12 Million JPY | -2.66% |
| 2012 Q3 | 191.14 Million JPY | -45.61% |
| 2012 Q1 | 288.11 Million JPY | 3.35% |
| 2012 FY | 282.95 Million JPY | -1.79% |
| 2012 Q4 | 275.86 Million JPY | 44.32% |
| 2012 Q2 | 351.4 Million JPY | 21.97% |
| 2011 FY | 288.11 Million JPY | -14.08% |
| 2011 Q4 | 278.77 Million JPY | -17.99% |
| 2011 Q1 | 335.33 Million JPY | 61.5% |
| 2011 Q3 | 339.92 Million JPY | -9.87% |
| 2011 Q2 | 377.15 Million JPY | 12.47% |
| 2010 FY | 335.33 Million JPY | 13.18% |
| 2010 Q2 | 251.79 Million JPY | -15.02% |
| 2010 Q3 | 294.75 Million JPY | 17.06% |
| 2010 Q1 | 296.27 Million JPY | 86.3% |
| 2010 Q4 | 207.64 Million JPY | -29.55% |
| 2009 Q3 | 188.09 Million JPY | 0.0% |
| 2009 Q4 | 159.03 Million JPY | -15.45% |
| 2009 FY | 296.27 Million JPY | 29.54% |
| 2009 Q1 | 228.72 Million JPY | -63.98% |
| 2008 Q4 | 635.06 Million JPY | 0.0% |
| 2008 FY | 228.72 Million JPY | -85.89% |
| 2007 FY | 1.62 Billion JPY | -15.17% |
| 2006 FY | 1.91 Billion JPY | 129.93% |
| 2005 FY | 831.24 Million JPY | 442.14% |
| 2004 FY | 153.32 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | -2683.799% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -142443.092% |
| GNI Group Ltd. | 26.34 Billion JPY | -243.138% |
| Linical Co., Ltd. | 10.3 Billion JPY | -777.137% |
| Trans Genic Inc. | 3.81 Billion JPY | -2270.81% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -15214.705% |
| Soiken Holdings Inc. | 697.02 Million JPY | -12867.721% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | -2892.239% |
| AnGes, Inc. | 2.78 Billion JPY | -3140.446% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -17498.67% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -25486.023% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | -5378.426% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -19035.608% |
| CanBas Co., Ltd. | 91.98 Million JPY | -98160.643% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | -8165.134% |
| RaQualia Pharma Inc. | 809.83 Million JPY | -11061.355% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -15123.729% |
| Kidswell Bio Corporation | 4.25 Billion JPY | -2024.739% |
| PeptiDream Inc. | 29.11 Billion JPY | -210.459% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -15855.516% |
| Ribomic Inc. | 155.8 Million JPY | -57912.053% |
| SanBio Company Limited | 2.25 Billion JPY | -3908.529% |
| Healios K.K. | 11.28 Billion JPY | -700.886% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -35872.603% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -24395.393% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -37328.208% |
| StemRIM | 187 Million JPY | -48235.829% |
| CellSource Co., Ltd. | 677.73 Million JPY | -13236.697% |
| FunPep Company Limited | 189.32 Million JPY | -47642.494% |
| Kringle Pharma, Inc. | 596.95 Million JPY | -15041.51% |
| Stella Pharma Corporation | 1.44 Billion JPY | -6161.248% |
| TMS Co., Ltd. | 97.68 Million JPY | -92426.282% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -98691.178% |
| Cuorips Inc. | 200.96 Million JPY | -44877.881% |
| K Pharma,Inc. | 209.13 Million JPY | -43120.136% |
| Takara Bio Inc. | 11.42 Billion JPY | -691.489% |
| ReproCELL Incorporated | 741.03 Million JPY | -12097.584% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | -9749.267% |
| StemCell Institute Inc. | 3.85 Billion JPY | -2247.459% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | -9849.903% |
| CellSeed Inc. | 301.04 Million JPY | -29924.548% |